GlassScriptPhysician profile
Khalid R Chaudry
NPI 1306895966
$2,504.87
in general payments reported to CMS, 2019-2025
16 companies · $519 in 2025
The $519 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.73 · 2020: $97.78 · 2021: $132 · 2022: $338 · 2023: $690 · 2024: $641 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,751 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,750.50 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $530.41 | 2020-2025 | Farxiga, Brilinta |
| Merck Sharp & Dohme LLC | $518.76 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $404.99 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $296.14 | 2022-2025 | |
| Amgen INC. | $102.07 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $92.00 | 2022-2025 | Lifevest |
| Novo Nordisk INC | $90.71 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $83.93 | 2024-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $77.98 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $61.74 | 2023-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.32 | 2019-2021 | |
| Amarin Pharma, INC. | $57.50 | 2019 | |
| Irhythm Technologies, INC. | $43.52 | 2023 | Zio Xt Patch |
| Boston Scientific Corporation | $37.16 | 2023 | Bodyguardian |
| Philips North America LLC | $27.05 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.59 | 2025 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Chaudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.